|
| Press Releases |
|
 |
|
| Thursday, April 14, 2016 |
|
|
Aricept Approved in the Philippines for New Indication as Treatment for Dementia with Lewy Bodies |
| Eisai Co., Ltd. announced today that its subsidiary in the Philippines, HI-Eisai Pharmaceutical Inc., has received approval for a new indication for the symptomatic treatment of dementia with Lewy bodies (DLB) for anti-Alzheimer's agent Aricept (donepezil hydrochloride) in the Philippines, and has commenced information provision activities. more info >> |
|
| Tuesday, April 5, 2016 |
|
|
Eisai Receives Positive CHMP Opinion on New Indicator for Anticancer Agent Halaven for Treatment of Advanced Liposarcoma |
| Eisai Co., Ltd. announced today that its European regional headquarters Eisai Europe Ltd. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on anticancer agent Halaven (eribulin mesylate) for treatment of adult patients with unresectable liposarcomas. more info >> |
|
| Thursday, March 31, 2016 |
|
|
Eisai Transfer the Rights to Investigational Anticancer Agent E7777 for European, U.S and Certain Emerging Markets to Dr. Reddy's Laboratories |
| Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the exclusive worldwide development and marketing rights (excluding Japan and Asia) for its investigational anticancer agent E7777 to Dr. Reddy's Laboratories Ltd. more info >> |
|
| Wednesday, March 30, 2016 |
|
|
Eisai Co., Ltd. and Ajinomoto Co., Inc. Announce Establishment of Gastrointestinal Specialty Pharma EA Pharma Co., Ltd. |
| Eisai Co., Ltd. and Ajinomoto Co., Inc. announced today that based on the integration agreement signed and announced on October 15, 2015, the gastrointestinal specialty pharma EA Pharma Co., Ltd. will be established through the splitting off of a portion of Eisai's gastrointestinal disease treatment. more info >> |
|
|
Eisai's Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2016 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that based on recent trends in business results, etc., the company has revised its full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016) previously announced on February 2, 2016. more info >> |
|
|
Eisai's Notice Concerning Shelf Registration for Issuance of Stock Options |
| Eisai Co., Ltd. ("the Company") today filed a shelf registration statement with the Kanto Local Finance Bureau for issuance of stock options in accordance with the Company's "Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders" ("the Policy"). more info >> |
|
| Tuesday, March 29, 2016 |
|
|
Eisai's In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) Approved in Japan |
| Eisai Co., Ltd. announced today that its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) has been approved in Japan as an adjunctive therapy for partial-onset seizures or primary generalized tonic-clonic seizures in patients with epilepsy showing inadequate response to other AEDs. more info >> |
|
| Tuesday, March 22, 2016 |
|
|
Eisai Withdraws New Drugs Application for Mecobalamin Ultra-High Dose Preparation as Treatment for Amyotrophic Lateral Sclerosis |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has withdrawn its new drug application for ultra-high dose Mecobalamin development code: E0302) as a treatment for amyotrophic lateral sclerosis (ALS) in Japan. more info >> |
|
| Thursday, March 17, 2016 |
|
|
Notice Regarding Discontinuation of Sales and Voluntary Recall of Egg White Lysozyme Preparation Neuzym |
| Eisai Co., Ltd. announced today that its pharmaceutical manufacturing and marketing subsidiary Sannova Co., Ltd. has been informed the results of deliberation of the Committee on Reevaluation of the Pharmaceutical Affairs and Food Sanitation Council's meeting held on March 17 regarding the egg white lysozyme preparation Neuzym (lysozyme hydrochloride, "lysozyme") which had been submitted for reevaluation. more info >> |
|
| Monday, February 15, 2016 |
|
|
Eisai and Sysmex Enter Comprehensive Agreement to Create Next-Generation Diagnostic Reagents in the Field of Dementia |
| Eisai Co., Ltd. and Sysmex Corporation jointly announced that the two companies have entered into a comprehensive non-exclusive collaboration agreement aimed at the creation of new diagnostics in the field of dementia. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
MyJCB App Wins Gold at A' Design Award & Competition 
Jun 2, 2025 12:00 JST
|
|
|
Fujitsu Technology Park's redevelopment project launch
Jun 2, 2025 11:23 JST
|
|
|
Wasion Holdings Subsidiaries Secure Over HK$253 Million in Contracts from State Grid's 2025 First Metering Equipment Tender
Jun 2, 2025 09:43 HKT/SGT
|
|
|
TransNusa Increases Scheduled Flight Frequency to Twice Daily
Jun 2, 2025 08:30 HKT/SGT
|
|
|
Hola Prime Launches Performance Coaching Initiative to Tackle the #1 Barrier to Trader Success: The Mind
May 30, 2025 19:00 HKT/SGT
|
|
|
Mitsubishi Corporation Establishes New Corporate Venture Capital Company
May 30, 2025 18:36 JST
|
|
|
The PropertyGuru Asia Property Awards (Middle East) return for 2025 edition with inaugural Dubai launch
May 30, 2025 14:00 HKT/SGT
|
|
|
Honda to Co-develop Refueling Port Connecting System for On-orbit Satellite Refueling with Astroscale
May 30, 2025 11:54 JST
|
|
|
IFS and NEC Strengthen their Strategic Partnership to Create New Value
May 30, 2025 10:11 JST
|
|
|
Genetec maintains profitability in Q3FY2025 on higher revenue
May 29, 2025 20:00 HKT/SGT
|
|
|
Naoris Protocol Raises $3M in Strategic Round Led by Mason Labs
May 29, 2025 19:00 HKT/SGT
|
|
|
MODONG Coffee Proudly Sponsors "G-DRAGON 2025 WORLD TOUR [Ubermensch] IN TAIPEI, presented by KGI FINANCIAL GROUP" as Official Sponsor
May 29, 2025 18:19 HKT/SGT
|
|
|
Mazda Production and Sales Results for April 2025
May 29, 2025 18:44 JST
|
|
|
Euro Manganese Closes C$11.2 million (A$12.3 million) Financing
May 29, 2025 16:09 HKT/SGT
|
|
|
First patient dosed in YK012 trial-the world's first TCE therapy for primary membranous nephropathy
May 29, 2025 15:49 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
